Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2017 07:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics Reports First Patient Treated in Phase 2 Study of Topical Radezolid for Treatment of Acne

NEW HAVEN, Conn., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT) a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
November 06, 2017 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics Announces Successful Completion of Merger

NEW HAVEN, Conn., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
October 30, 2017 08:01 ET | Source: Melinta Therapeutics

Melinta Therapeutics Announces FDA Clearance of Antimicrobial Susceptibility Tests Concurrent with Baxdela Launch in the United States

NEW HAVEN, Conn., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, announced...
October 24, 2017 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics Publication Reinforces Baxdela Tolerability and Activity in Patients with MRSA Infections and Challenging Comorbidities

NEW HAVEN, Conn., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
October 10, 2017 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics’ Topical Radezolid Well Tolerated in Phase 1 Study for Treatment of Acne

NEW HAVEN, Conn., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
October 04, 2017 13:13 ET | Source: Melinta Therapeutics

Melinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeek

NEW HAVEN, Conn., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
September 26, 2017 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics Provides for Distribution of Delafloxacin to 19 Countries via Extended Agreement with Eurofarma Laboratórios

NEW HAVEN, Conn., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing novel antibiotics to treat serious bacterial infections, announced...
September 25, 2017 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials and In Vitro Performance against Isolates of Resistant CABP and other Infections

NEW HAVEN, Conn., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, announced...
September 22, 2017 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics to Participate in Two Upcoming Investor Conferences

NEW HAVEN, Conn., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing novel antibiotics to treat serious bacterial infections, announced...
September 18, 2017 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics Publication Highlights Baxdela Activity Against Fluoroquinolone-Non-Susceptible MRSA Pathogens

NEW HAVEN, Conn., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing novel antibiotics to treat serious bacterial infections, announced...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right